Main > ONCOLOGY (**) > Lymphoma>NHL>B-Cell>SLL>R/R> > TREAT.: > CN. I. Orelabrutinib
CN. I. Orelabrutinib's subsections
(*) CN Approval Date: 2020. 12.27
Company
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 2
Patent>UpDate: 2021. 02.16.
CN. I. Orelabrutinib's products
This section has no products